The global Drug based on CAR T-Cell market size was valued at US$ 425 million in 2024 and is forecast to a readjusted size of USD 673 million by 2031 with a CAGR of 6.8% during review period.
Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy, because it involves altering the genes inside T cells to help them attack the cancer.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Drug based on CAR T-Cell market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Drug based on CAR T-Cell market size and forecasts, in consumption value ($ Million), 2020-2031
Global Drug based on CAR T-Cell market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Drug based on CAR T-Cell market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Drug based on CAR T-Cell market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Drug based on CAR T-Cell
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Drug based on CAR T-Cell market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Gilead Sciences, Bristol-Myers Squibb, J & J, JW Therapeutics, FOSUNKite, CARsgen Therapeutics (Pipeline), CARsgen Therapeutics, Autolus Therapeutics, Sorrento Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Drug based on CAR T-Cell market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
CD19-targeted
BCMA-targeted
麻豆原创 segment by Application
Lymphoma
Multiple Myeloma
麻豆原创 segment by players, this report covers
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Drug based on CAR T-Cell product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Drug based on CAR T-Cell, with revenue, gross margin, and global market share of Drug based on CAR T-Cell from 2020 to 2025.
Chapter 3, the Drug based on CAR T-Cell competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Drug based on CAR T-Cell market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Drug based on CAR T-Cell.
Chapter 13, to describe Drug based on CAR T-Cell research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Drug based on CAR T-Cell by Type
1.3.1 Overview: Global Drug based on CAR T-Cell 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Drug based on CAR T-Cell Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 CD19-targeted
1.3.4 BCMA-targeted
1.4 Global Drug based on CAR T-Cell 麻豆原创 by Application
1.4.1 Overview: Global Drug based on CAR T-Cell 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Lymphoma
1.4.3 Multiple Myeloma
1.5 Global Drug based on CAR T-Cell 麻豆原创 Size & Forecast
1.6 Global Drug based on CAR T-Cell 麻豆原创 Size and Forecast by Region
1.6.1 Global Drug based on CAR T-Cell 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Drug based on CAR T-Cell 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Drug based on CAR T-Cell 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Drug based on CAR T-Cell 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Drug based on CAR T-Cell 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Drug based on CAR T-Cell 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Drug based on CAR T-Cell 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Drug based on CAR T-Cell Product and Solutions
2.1.4 Novartis Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Novartis Recent Developments and Future Plans
2.2 Gilead Sciences
2.2.1 Gilead Sciences Details
2.2.2 Gilead Sciences Major Business
2.2.3 Gilead Sciences Drug based on CAR T-Cell Product and Solutions
2.2.4 Gilead Sciences Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Gilead Sciences Recent Developments and Future Plans
2.3 Bristol-Myers Squibb
2.3.1 Bristol-Myers Squibb Details
2.3.2 Bristol-Myers Squibb Major Business
2.3.3 Bristol-Myers Squibb Drug based on CAR T-Cell Product and Solutions
2.3.4 Bristol-Myers Squibb Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.4 J & J
2.4.1 J & J Details
2.4.2 J & J Major Business
2.4.3 J & J Drug based on CAR T-Cell Product and Solutions
2.4.4 J & J Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 J & J Recent Developments and Future Plans
2.5 JW Therapeutics
2.5.1 JW Therapeutics Details
2.5.2 JW Therapeutics Major Business
2.5.3 JW Therapeutics Drug based on CAR T-Cell Product and Solutions
2.5.4 JW Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 JW Therapeutics Recent Developments and Future Plans
2.6 FOSUNKite
2.6.1 FOSUNKite Details
2.6.2 FOSUNKite Major Business
2.6.3 FOSUNKite Drug based on CAR T-Cell Product and Solutions
2.6.4 FOSUNKite Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 FOSUNKite Recent Developments and Future Plans
2.7 CARsgen Therapeutics (Pipeline)
2.7.1 CARsgen Therapeutics (Pipeline) Details
2.7.2 CARsgen Therapeutics (Pipeline) Major Business
2.7.3 CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Product and Solutions
2.7.4 CARsgen Therapeutics (Pipeline) Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 CARsgen Therapeutics (Pipeline) Recent Developments and Future Plans
2.8 CARsgen Therapeutics
2.8.1 CARsgen Therapeutics Details
2.8.2 CARsgen Therapeutics Major Business
2.8.3 CARsgen Therapeutics Drug based on CAR T-Cell Product and Solutions
2.8.4 CARsgen Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 CARsgen Therapeutics Recent Developments and Future Plans
2.9 Autolus Therapeutics
2.9.1 Autolus Therapeutics Details
2.9.2 Autolus Therapeutics Major Business
2.9.3 Autolus Therapeutics Drug based on CAR T-Cell Product and Solutions
2.9.4 Autolus Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Autolus Therapeutics Recent Developments and Future Plans
2.10 Sorrento Therapeutics
2.10.1 Sorrento Therapeutics Details
2.10.2 Sorrento Therapeutics Major Business
2.10.3 Sorrento Therapeutics Drug based on CAR T-Cell Product and Solutions
2.10.4 Sorrento Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Sorrento Therapeutics Recent Developments and Future Plans
2.11 Mustang Bio
2.11.1 Mustang Bio Details
2.11.2 Mustang Bio Major Business
2.11.3 Mustang Bio Drug based on CAR T-Cell Product and Solutions
2.11.4 Mustang Bio Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Mustang Bio Recent Developments and Future Plans
2.12 Bluebird Bio
2.12.1 Bluebird Bio Details
2.12.2 Bluebird Bio Major Business
2.12.3 Bluebird Bio Drug based on CAR T-Cell Product and Solutions
2.12.4 Bluebird Bio Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Bluebird Bio Recent Developments and Future Plans
2.13 Cellectis
2.13.1 Cellectis Details
2.13.2 Cellectis Major Business
2.13.3 Cellectis Drug based on CAR T-Cell Product and Solutions
2.13.4 Cellectis Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Cellectis Recent Developments and Future Plans
2.14 Allogene Therapeutics
2.14.1 Allogene Therapeutics Details
2.14.2 Allogene Therapeutics Major Business
2.14.3 Allogene Therapeutics Drug based on CAR T-Cell Product and Solutions
2.14.4 Allogene Therapeutics Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Allogene Therapeutics Recent Developments and Future Plans
2.15 Celyad
2.15.1 Celyad Details
2.15.2 Celyad Major Business
2.15.3 Celyad Drug based on CAR T-Cell Product and Solutions
2.15.4 Celyad Drug based on CAR T-Cell Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Celyad Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Drug based on CAR T-Cell Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Drug based on CAR T-Cell by Company Revenue
3.2.2 Top 3 Drug based on CAR T-Cell Players 麻豆原创 Share in 2024
3.2.3 Top 6 Drug based on CAR T-Cell Players 麻豆原创 Share in 2024
3.3 Drug based on CAR T-Cell 麻豆原创: Overall Company Footprint Analysis
3.3.1 Drug based on CAR T-Cell 麻豆原创: Region Footprint
3.3.2 Drug based on CAR T-Cell 麻豆原创: Company Product Type Footprint
3.3.3 Drug based on CAR T-Cell 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Drug based on CAR T-Cell Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Drug based on CAR T-Cell 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Drug based on CAR T-Cell Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Drug based on CAR T-Cell 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Drug based on CAR T-Cell Consumption Value by Type (2020-2031)
6.2 North America Drug based on CAR T-Cell 麻豆原创 Size by Application (2020-2031)
6.3 North America Drug based on CAR T-Cell 麻豆原创 Size by Country
6.3.1 North America Drug based on CAR T-Cell Consumption Value by Country (2020-2031)
6.3.2 United States Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Drug based on CAR T-Cell Consumption Value by Type (2020-2031)
7.2 Europe Drug based on CAR T-Cell Consumption Value by Application (2020-2031)
7.3 Europe Drug based on CAR T-Cell 麻豆原创 Size by Country
7.3.1 Europe Drug based on CAR T-Cell Consumption Value by Country (2020-2031)
7.3.2 Germany Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Drug based on CAR T-Cell Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Drug based on CAR T-Cell Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Drug based on CAR T-Cell 麻豆原创 Size by Region
8.3.1 Asia-Pacific Drug based on CAR T-Cell Consumption Value by Region (2020-2031)
8.3.2 China Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Drug based on CAR T-Cell Consumption Value by Type (2020-2031)
9.2 South America Drug based on CAR T-Cell Consumption Value by Application (2020-2031)
9.3 South America Drug based on CAR T-Cell 麻豆原创 Size by Country
9.3.1 South America Drug based on CAR T-Cell Consumption Value by Country (2020-2031)
9.3.2 Brazil Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Drug based on CAR T-Cell Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Drug based on CAR T-Cell Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Drug based on CAR T-Cell 麻豆原创 Size by Country
10.3.1 Middle East & Africa Drug based on CAR T-Cell Consumption Value by Country (2020-2031)
10.3.2 Turkey Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Drug based on CAR T-Cell 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Drug based on CAR T-Cell 麻豆原创 Drivers
11.2 Drug based on CAR T-Cell 麻豆原创 Restraints
11.3 Drug based on CAR T-Cell Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Drug based on CAR T-Cell Industry Chain
12.2 Drug based on CAR T-Cell Upstream Analysis
12.3 Drug based on CAR T-Cell Midstream Analysis
12.4 Drug based on CAR T-Cell Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite
CARsgen Therapeutics (Pipeline)
CARsgen Therapeutics
Autolus Therapeutics
Sorrento Therapeutics
Mustang Bio
Bluebird Bio
Cellectis
Allogene Therapeutics
Celyad
听
听
*If Applicable.
